Low-level transferable resistance to ceftazidime was detected in seven strains of Klebsiella pneumoniae and one strain of Escherichia coli. Six of the Klebsiella strains and the E. coli strain were shown to produce a novel P-lactamase (CAZ-lo) with a pl of 5.6 that hydrolyzed broad-spectrum cephalosporins at low but comparable levels. One strain of K. pneumoniae was of a serotype different from that of the other strains and produced a plasmid-encoded cefuroximase (FUR) with a pI of 7.5 that mediated moderate levels of resistance to different broad-spectrum cephalosporins. High-level resistance to ceftazidime was detected in one other strain of K. pneumoniae, which produced a ,-lactamase with a pl of 6.5 (CAZ-hi). Apart from its pl, this enzyme differed from CAZ-lo by a specific and high hydrolytic activity against ceftazidime. The epidemiological context suggested that CAZ-hi may be a mutant of CAZ-lo, and this hypothesis was supported by the isolation of laboratory mutants of CAZ-lo showing properties identical to those of the clinical CAZ-hi enzyme.
Initial in vitro tests determining the enzymatic stability of the newer P-lactams showed considerable stability to both chromosomal and R-plasmid-mediated enzymes. However, since the intensive use of broad-spectrum cephalosporins was begun, several failures due to the emergence of mutants that hyperproduce a chromosomal cephalosporinase, known as class I P-lactamase by the classification of Richmond and Sykes, have been described (18, 19) . More recently, transferable resistance to these agents was also described. Strains of Klebsiella pneumoniae and Serratia marcescens with transferable resistance to broad-spectrum cephalosporins were first described in Germany (12) and found to produce a novel plasmid-determined P-lactamase, designated SHV-2 (11) . From 1985 on, nosocomial outbreaks of multiresistant K. pneumoniae and other species were reported in French hospitals (4, 10, 22) . The resistance was ascribed to another new broad-spectrum P-lactamase, CTX-1, that displayed high-level hydrolytic activity against cefotaxime and ceftazidime (13) . More recently, strains of K. pneumoniae and Escherichia coli that are resistant to ceftazidime but remain more or less susceptible to other broad-spectrum cephalosporins were reported in France (5, 17) , the Federal Republic of Germany (3) , and the United Kingdom (24) . In this article, we report three novel plasmid-mediated P-lactamases detected in strains from Belgium with decreased susceptibilities to ceftazidime.
MATERIALS AND METHODS
Bacterial strains. During a period of 4 weeks, seven strains of K. pneumoniae and one strain of E. coli with partial resistance to ceftazidime were isolated from several patients in the intensive care unit. These strains were recognized by their intermediate zone diameters on standard antibiograms and by marked synergism when an amoxicillin-clavulanic acid disk was placed beside the ceftazidime disk. All but one of the Klebsiella strains belonged to serotype 54, phage type 2,4. These strains and the E. coli isolate had identical * Corresponding author.
patterns of resistance to ,B-lactam antibiotics (designated CAZ-lo) and the same associated resistances to non-alactam antibiotics. One Klebsiella strain had a different pattern of susceptibility to ,B-lactam antibiotics as well as to non-3-lactam antibiotics. It belonged to serotype 28, phage type 2,5,6 and was highly resistant to cefuroxime (FUR). In addition to these isolates with low-level resistance to ceftazidime, we isolated during the same period a K. pneumoniae strain, serotype 54, phage type 2,4, with high-level resistance to this antibiotic (CAZ-hi). It was cultured from the sputum of a patient who had earlier harbored a Klebsiella strain with the CAZ-lo phenotype. All the patients were hospitalized for several weeks and had received several courses of therapy with a broad-spectrum cephalosporin or aztreonam and with an aminoglycoside. Cefuroxime was not used during the observation period but had been first-line therapy several months earlier.
For transfer experiments, E. coli K-12 C600 Rif' (2) and Dll Nalr (provided by M. Van Montagu from the Laboratory of Genetics, University of Ghent, Ghent, Belgium) were used.
Antibiotics. Standard powders were provided by the companies as follows: ampicillin and clavulanic acid, Beecham Laboratories; sulbactam, Pfizer Inc.; piperacillin, Lederle Laboratories; cephaloridine, cefuroxime, and ceftazidime, Glaxo Pharmaceuticals, Ltd.; cefoxitin and imipenem, Merck Sharp & Dohme; cefotetan, Imperial Chemical Industries; cefotaxime, Hoechst; ceftriaxone, Roche Diagnostics; aztreonam, E. R. Squibb & Sons. Disks for antibiograms were obtained from bioMerieux Diagnostics.
Susceptibility testing. MICs were determined by an agar dilution technique on Mueller-Hinton agar. The organisms were grown overnight in tryptic soy broth, diluted to an inoculum density of 107 CFU/ml, and spotted with a multipoint inoculator (104 CFU per spot). The plates were incubated at 37°C for 18 h. Agar diffusion susceptibility tests were performed using current National Committee for Clinical Laboratory Standards recommendations.
Transfer of resistance. Overnight cultures in tryptic soy broth of the clinical isolates and the recipient were mixed at a volume ratio of 1:1, and the suspension was incubated stationarily at 37°C for 16 h. Transconjugants were selected on tryptic soy agar containing ceftazidime (1 ,ugIml) and either rifampin (100 ,ug/ml) or nalidixic acid (50 ,ug/ml). ,-Lactamase preparation. Overnight cultures in brain heart infusion broth were diluted 10-fold with fresh broth and incubated with shaking for 5 h at 37°C. Cells were harvested by centrifugation at 4°C, washed with 0.067 M phosphate buffer (pH 7.0), and suspended in 1/100 of the original volume. After sonication, crude extracts were obtained by centrifugation at 20,000 x g.
,-Lactamase assay. ,-Lactamase activities against the cephalosporins and aztreonam were determined by the spectrophotometric method of O'Callaghan et al. (16) in a Beckman spectrophotometer at 37°C in 67 mM phosphate buffer (pH 7.0). The absorption maxima were as described by Seeberg et al. (20) , except for cephaloridine, which was measured at 260 nm. Substrate concentrations of 0.1 mM were used, and initial rates of hydrolysis were related to that of cephaloridine (100%). Specific activities were related to protein concentrations as determined with the Folin reagent (14) .
Biological inactivation of the antibiotics by crude enzyme extracts was further detected by a plate test bioassay method (8) . To disks containing 30 jig of antibiotic, 10 iil of diluted sonic extract was added and incubated at 37°C for 1 h. The disks were then applied on Mueller-Hinton plates seeded with a susceptible strain of E. coli K-12. Heat-inactivated extracts were always run as a control to the specificity of the experiment.
Isoelectric focusing. Analytical isoelectric focusing was performed in commercially prepared polyacrylamide gels (pH 3.5 to 9.5) according to the instructions of the manufacturer (LKB, Bromma, Sweden) by using a Pharmacia flatbed apparatus. pIs were measured by using a broad-range mixture of pI marker proteins from LKB. The ,B-lactamase activities were revealed with a solution of 0.5 mg of nitrocefin per ml (15 ranged between 2 x 1O-' and 2 x 10-6 when related to the cell number of the donor strain. Transconjugants showed the same pattern of resistance to ,B-lactam antibiotics as did their respective donors (Table 1 ). Resistance to non-,-lactam antibiotics, as mentioned above, was cotransferred in all matings ( Table 2) .
Characterization of J8-lactamases. Isoelectric focusing was performed on the crude extracts of the clinical isolates and their E. coli transconjugants selected on ceftazidime (Table  2) . K. pneumoniae CAZ-lo strains all showed two enzymes with pIs of 7.6 and 5.6, respectively, and transferred the latter enzyme to E. coli K-12. K. pneumoniae CAZ-hi had the same enzyme with a pl of 7.6 and a second band at 6.5 which appeared in its transconjugant. The clinical E. coli strain with the CAZ-lo phenotype produced a transferable enzyme with a pI of 5.6, as did the Klebsiella strains with the same phenotype, and an additional band at 5.4 which may represent a TEM-1 enzyme but which was not transferred after conjugation and selection with ceftazidime. In K. pneumoniae FUR, a transferable enzyme focusing at 7.5 was found in addition to a weak band at 7.6. The specific P-lactamase activities and substrate profiles of the transferred enzymes are shown in Table 3 in comparison with that of TEM-1 ,B-lactamase. All enzymes originating from CAZ-lo phenotypes had an identical profile, characterized by a low but definite hydrolytic rate with ceftazidime and cefotaxime. The CAZ-hi enzyme differed by its pronounced activity on ceftazidime but was otherwise very similar to CAZ-lo. The most distinguishing feature of the enzyme from K. pneumoniae FUR, on the other hand, was its high hydrolysis rate for cefuroxime.
Biological inactivation of 13-lactam antibiotics. In order to clarify further the role of the ,-lactamase as a resistance determinant, we assessed the ability of crude extracts of the transferred ,B-lactamases to inactivate the antibiotics in a biological assay. Crude extracts of the three different Ilactamases inactivated cefuroxime, cefotaxime, ceftazidime, and aztreonam, although to various degrees, but they were without any effect against cefoxitin. The addition of clavulanic acid restored completely the activity of the different compounds. The most interesting element of these experiments was the inactivation of aztreonam, which could not be proved to be hydrolyzed in the spectrophotometric assay.
Isolation of mutants from strains with CAZ-lo ,3-lactamase.
Since both CAZ-lo and CAZ-hi P-lactamases were found on plasmids with identical associated resistance markers and moreover were found in the same patient within a short period, we speculated that the latter enzyme could have evolved as a mutant from the former. a Hydrolysis of cephaloridine is 100lo.
4). The substrate profiles of the mutated 1-lactamases were most similar to that of CAZ-hi 13-lactamase, with a relative rate of ceftazidime hydrolysis of more than 40%. The increased resistance of Tr-2326mut (a C600 Rif' transconjugant) could be transferred further to a nalidixic acid-resistant substrain of E. coli Dll, proving that the mutation was associated with a plasmid-borne gene (data not shown). DISCUSSION Initial reports of transferable resistance to broad-spectrum cephalosporins and aztreonam came from the Federal Republic of Germany (12) and France (22) and were due to broad-spectrum P-lactamases designated SHV-2 (11) and CTX-1 (10), respectively. These enzymes have a broad hydrolytic activity against most newer P-lactams, except the a-methoxy compounds and imipenem (13) . SHV-2 enzymes were later found in France as well (9) . More recently, there have been reports from several countries of transferable resistance to ceftazidime in strains more or less susceptible to other broad-spectrum compounds (3, 5, 7, 17, 21, 24) .
Several novel extended-spectrum P-lactamases seem to be implicated (for a review, see Sougakoff et al. [23] ). These authors as well as others (11) provided evidence that the enzymes may be derived from older P-lactamases by mutation.
During a relatively short observation period, we isolated several strains of K. pneumoniae and one E. coli strain with reduced susceptibilities to ceftazidime from intensive care patients. Characterization of the resistance mechanism and comparison with previously described enzymes seemed to be highly relevant. Three different plasmidic P-lactamases could be designated: CAZ-lo, occurring in six K. pneumoniae serotype 54 strains and one E. coli strain; CAZ-hi, occurring in one K. pneumoniae strain of the same serotype; and FUR, which was detected in a K. pneumoniae serotype 28 strain.
Caz-lo had a pI of 5.6 and displayed a low but definite hydrolysis rate to ceftazidime as well as to cefotaxime. The pl of this enzyme is close to that of two other ceftazidimases, CAZ-1 (pl 5.55 [17] ) and RHH-1 (pl 5.5 [24] ), both of which were detected in K. pneumoniae. However, RHH-1 displayed high hydrolytic efficiency against cefotaxime and ceftazidime and mediated a higher resistance to cefotaxime (2 to 8 ,ug/ml) than did our enzyme. The same holds true for the CAZ-1 enzyme, but it should nevertheless be noted that substrate profiles were determined as Vmax values by these authors. It seems unlikely that differences in the levels of resistance are the consequence of different amounts of the same enzyme. CAZ-lo mediated an identical level of resistance in all species it was detected in. Kitzis et al. (10) reported almost the same observation for CTX-1 ,-lactamase. The substrate profile of CAZ-lo resembles more closely that of enzyme TEM-7, which was recently detected by Gutmann and co-workers (7) in a clinical isolate of Citrobacter freundii. This enzyme hydrolyzed ceftazidime and cefotaxime at nearly equal rates, which were 1 to 2% that of penicillin G (Vmax values), and mediated resistance to ceftazidime (32 ,ug/ml) but not to cefotaxime (0.5 ,ug/ml). Moreover, the same authors were able to obtain a TEM-2 derivative which showed characteristics similar to those of TEM-7, TEM-201, by in vitro selection in the presence of ceftazidime. Although the pls of TEM-7 and TEM-201 (both 5.41) are different from that of our enzyme, it is tempting to speculate that these three enzymes are derived from TEM-2 by single mutations under the selective pressure of ceftazidime (23) . CAZ-lo and TEM-7 also seem similar with respect to the apparent paradox presented by their hydrolytic efficiency against cefotaxime and ceftazidime and the resistance mediated to these two antibiotics.
One isolate of K. pneumoniae had high-level resistance to ceftazidime. The enzyme responsible, designated CAZ-hi, was similar to CAZ-lo except for its pl (6.5) and its high rate of hydrolysis of ceftazidime. The P-lactamase was transferable on an R plasmid with identical associated resistances to non-p-lactam antibiotics as the plasmid encoding CAZ-lo.
Moreover, since CAZ-lo and CAZ-hi were both detected in a Klebsiella strain of the same serotype isolated from the same patient, the latter enzyme may be a mutant of the former. This hypothesis was strongly supported by the in vitro selection of a CAZ-lo derivative, CAZ-lomut, which had characteristics similar to those of CAZ-hi and which mediated identical resistance levels. To our knowledge, this is the first observation of such a conversion both in vivo and in vitro. The pl of CAZ-hi (6.5) is quite different from those of previously described ceftazidimases, which are in the pl range of 5.5 to 6.0 (3, 5, 17, 21, 24) . On the other hand, resistance levels to ,B-lactam antibiotics mediated by our enzyme closely resemble those of these other ceftazidimases, especially the enzyme described by Bauernfeind (3) . Interestingly, CAZ-hi hydrolyzed all newer cephalosporins except ceftazidime at levels comparable to that of CAZ-lo, although it mediated cross resistance to these antibiotics, especially aztreonam. The specific activity of CAZ-lo and CAZ-hi in E. coli K-12 was almost the same, so that a different hydrolytic efficiency is more likely to be responsible for the effect on resistance. Determination of kinetic constants are presently under way to gain more insight into the enzymatic differences between the two enzymes.
The strain of K. pneumoniae producing FUR was highly resistant to cefuroxime and had MICs of 16 ,ug of ceftazidime, ceftriaxone, and aztreonam per ml. This resistance profile resembles that of indole-positive Klebsiella strains, which produce chromosomal broad-spectrum P-lactamases (8) . FUR had a pl of 7.5 and seems to be related in this respect to the SHV-2 enzymes described in Germany (11) and France (9) . However, the original SHV-2 enzyme described by Kliebe (11) did not hydrolyze cefuroxime to a high degree, nor did it mediate resistance to this antibiotic.
The French workers, on the other hand, did not comment on the interaction with cefuroxime. To our knowledge, only the chromosomal ,B-lactamases of Klebsiella oxytoca and Proteus vulgaris are known as specific cefuroximases.
The resistance mediated by the three novel P-lactamases was significantly counteracted by both clavulanic acid and sulbactam. This property seems to be common to all novel plasmid-encoded 1-lactamases described so far which hydrolyze broad-spectrum cephalosporins.
